Haleos Labs Ltd.
1,617.25
INR
+10.20
(+0.63%)
ISIN
INE320X01016
Return %
Stock
S&P 500
1Y
44.22
14.20
3Y
211.37
81.12
5Y
95.32
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Talluri Veera V S N Murthy
- Full Time Employees
- 611
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Plot No. 19-III Hyderabad TS India 500096
- IPO Date
- Aug 17, 2017
- Website
- smslife.in
- Similar Companies
- Business
- Haleos Labs Limited, a developer and manufacturer of Active Pharmaceutical Ingredients (APIs) and their intermediates, operates as a Hyderabad-based pharmaceutical company with global export capabilities. Founded in 1990 and formerly known as SMS Lifesciences India Limited, the company supplies a broad portfolio of API products and related intermediates across multiple therapeutic areas and maintains manufacturing facilities at Kazipally and Jeedimetla in Hyderabad, with ongoing capacity expansion to support domestic and international demand. Main products and services APIs across multiple therapeutic classes; API intermediates and related chemical intermediates; contract manufacturing for pharmaceutical ingredients; export of pharmaceuticals and chemical products; custom synthesis and scale-up services for API development; regulatory and quality-compliance support for global markets; supply chain services for API distribution. Latest major company changes Strategic name change from SMS Lifesciences India Limited to Haleos Labs Limited in August 2025; realignment of corporate structure toward an independent listed entity with expanded brand identity; ongoing expansion of multi-location manufacturing footprint in Hyderabad to increase output capacity; strengthening export operations to broaden international footholds; formation of alliances to enhance API portfolio breadth and regulatory readiness. Additional context Industry and business segments: Pharmaceuticals, active pharmaceutical ingredients (APIs) and their intermediates, contract development and manufacturing organization (CDMO) activities, global API export. Target markets: pharmaceutical manufacturers and generic/drug development companies worldwide; customer types include multinational pharmaceutical firms and regional API buyers. Geographic operations: India (headquarters in Hyderabad, Telangana state) with exporting reach to global markets; subsidiaries or parent relationships include historical linkage to SMS Pharmaceuticals Limited through ownership and branding transitions. Founding year: 1990; headquarters: Hyderabad, India. Subsidiaries and corporate relationships Historically linked to SMS Pharmaceuticals Limited, with current corporate branding under Haleos Labs Limited; engages in strategic partnerships and alliances to enhance API portfolios and manufacturing capabilities.